217 related articles for article (PubMed ID: 30576871)
21. Molecular and Immune Correlates of PDCD1 (PD-1), PD-L1 (CD274), and PD-L2 (PDCD1LG2) DNA Methylation in Triple Negative Breast Cancer.
Ralser DJ; Klümper N; Gevensleben H; Zarbl R; Kaiser C; Landsberg J; Hölzel M; Strieth S; Faridi A; Abramian A; Dietrich D
J Immunother; 2021 Oct; 44(8):319-324. PubMed ID: 34347720
[TBL] [Abstract][Full Text] [Related]
22. Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer.
Santarpia L; Bottai G; Kelly CM; Győrffy B; Székely B; Pusztai L
Oncologist; 2016 Sep; 21(9):1063-78. PubMed ID: 27384237
[TBL] [Abstract][Full Text] [Related]
23. Clinical significance of PD-1/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinoma.
Ma LJ; Feng FL; Dong LQ; Zhang Z; Duan M; Liu LZ; Shi JY; Yang LX; Wang ZC; Zhang S; Ding ZB; Ke AW; Cao Y; Zhang XM; Zhou J; Fan J; Wang XY; Gao Q
Theranostics; 2018; 8(20):5690-5702. PubMed ID: 30555574
[No Abstract] [Full Text] [Related]
24. Prognostic value of programed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas.
Nakano T; Takizawa K; Uezato A; Taguchi K; Toh S; Masuda M
Oral Oncol; 2019 Mar; 90():30-37. PubMed ID: 30846173
[TBL] [Abstract][Full Text] [Related]
25. PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Menguy S; Prochazkova-Carlotti M; Beylot-Barry M; Saltel F; Vergier B; Merlio JP; Pham-Ledard A
Am J Surg Pathol; 2018 Mar; 42(3):326-334. PubMed ID: 29112015
[TBL] [Abstract][Full Text] [Related]
26.
Saigi M; Alburquerque-Bejar JJ; Mc Leer-Florin A; Pereira C; Pros E; Romero OA; Baixeras N; Esteve-Codina A; Nadal E; Brambilla E; Sanchez-Cespedes M
Clin Cancer Res; 2018 Sep; 24(18):4579-4587. PubMed ID: 29898990
[No Abstract] [Full Text] [Related]
27. Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types.
Budczies J; Denkert C; Győrffy B; Schirmacher P; Stenzinger A
BMC Med Genomics; 2017 Dec; 10(1):74. PubMed ID: 29212506
[TBL] [Abstract][Full Text] [Related]
28. Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies.
Devereaux KA; Charu V; Zhao S; Charville GW; Bangs CD; van de Rijn M; Cherry AM; Natkunam Y
Hum Pathol; 2018 Dec; 82():39-45. PubMed ID: 30539796
[TBL] [Abstract][Full Text] [Related]
29. Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer.
Huang RSP; Li X; Haberberger J; Sokol E; Severson E; Duncan DL; Hemmerich A; Edgerly C; Williams E; Elvin J; Vergilio JA; Killian JK; Lin D; Hiemenz M; Xiao J; McEwan D; Holmes O; Danziger N; Erlich R; Frampton G; Cohen MB; McGregor K; Reddy P; Cardeiro D; Anhorn R; Venstrom J; Alexander B; Brown C; Pusztai L; Ross JS; Ramkissoon SH
Oncologist; 2020 Nov; 25(11):943-953. PubMed ID: 32869930
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive assessment of PD-L1 and PD-L2 dysregulation in gastrointestinal cancers.
Zhao Q; Guo J; Zhao Y; Shen J; Kaboli PJ; Xiang S; Du F; Wu X; Li M; Wan L; Li X; Wen Q; Li J; Zou C; Xiao Z
Epigenomics; 2020 Dec; 12(24):2155-2171. PubMed ID: 33337915
[No Abstract] [Full Text] [Related]
31. Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications.
Li SD; Ma M; Li H; Waluszko A; Sidorenko T; Schadt EE; Zhang DY; Chen R; Ye F
Genome Med; 2017 Oct; 9(1):89. PubMed ID: 29082853
[TBL] [Abstract][Full Text] [Related]
32. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
Liu J; Liu Y
Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
[TBL] [Abstract][Full Text] [Related]
33. Nicotine treatment regulates PD-L1 and PD-L2 expression via inhibition of Akt pathway in HER2-type breast cancer cells.
Murayama MA; Takada E; Takai K; Arimitsu N; Shimizu J; Suzuki T; Suzuki N
PLoS One; 2022; 17(1):e0260838. PubMed ID: 35085258
[TBL] [Abstract][Full Text] [Related]
34. Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer.
Sivapiragasam A; Ashok Kumar P; Sokol ES; Albacker LA; Killian JK; Ramkissoon SH; Huang RSP; Severson EA; Brown CA; Danziger N; McGregor K; Ross JS
Cancer Med; 2021 Jan; 10(1):53-61. PubMed ID: 33314633
[TBL] [Abstract][Full Text] [Related]
35. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
36. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
[TBL] [Abstract][Full Text] [Related]
37. Clinical genomic profiling to identify actionable alterations for very early relapsed triple-negative breast cancer patients in the Chinese population.
Wang L; Zhai Q; Lu Q; Lee K; Zheng Q; Hong R; Wang S
Ann Med; 2021 Dec; 53(1):1358-1369. PubMed ID: 34396843
[TBL] [Abstract][Full Text] [Related]
38. Tumor mutation burden, immune checkpoint crosstalk and radiosensitivity in single-cell RNA sequencing data of breast cancer.
Jang BS; Han W; Kim IA
Radiother Oncol; 2020 Jan; 142():202-209. PubMed ID: 31767471
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis.
Kim HM; Lee J; Koo JS
BMC Cancer; 2017 Oct; 17(1):690. PubMed ID: 29041905
[TBL] [Abstract][Full Text] [Related]
40. Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma.
Wang Y; Wenzl K; Manske MK; Asmann YW; Sarangi V; Greipp PT; Krull JE; Hartert K; He R; Feldman AL; Maurer MJ; Slager SL; Nowakowski GS; Habermann TM; Witzig TE; Link BK; Ansell SM; Cerhan JR; Novak AJ
Blood Cancer J; 2019 Aug; 9(9):73. PubMed ID: 31471540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
